Entinostat is under clinical development by Taizhou Yiteng Jingang Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Entinostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Entinostat overview
Entinostat (Jingzhuda) is an antineoplastic agent. It is formulated as tablets for oral route of administration. Jingzhuda is indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER-2)-negative breast cancer who have relapsed or progressed after endocrine therapy and for advanced or metastatic breast cancer.
Entinostat is under development for the treatment of metastatic HER2- breast cancer, solid tumors, T-cell lymphomas and unspecified B-cell lymphomas. The drug candidate is a new molecular entity which is administered through oral route. It targets histone deacetylase 1. The drug candidate was under development for the treatment of relapsed or refractory acute lymphocytic leukemia, metastatic breast cancer and refractory acute myelocytic leukemia, triple negative breast cancer, small cell lung cancer and metastatic brain tumor, metastatic uveal melanoma, metastatic colorectal cancer, fallopian tube cancer, peritoneal cancer, epithelial ovarian cancer, metastatic renal cell carcinoma, metastatic melanoma, follicular lymphoma, myelodysplastic syndrome, chronic myelocytic leukemia, acute myelocytic leukemia, pancreatic ductal adenocarcinoma, cholangiocarcinoma, non-small cell lung cancer, adenoid cystic carcinoma, muscle invasive bladder cancer, refractory or relapsed Hodgkin lymphoma, endometrioid endometrial adenocarcinoma, muscle invasive bladder cancer, recurrent or refractory CNS tumors and lymphoma.
It was also under development for human papillomavirus (HPV) associated cancers, including metastatic solid tumors, lung cancer and esophagus cancer, colon cancer, cervical cancer, peripheral T-cell lymphoma (PTCL), oropharyngeal cancer, anal cancer, colorectal cancer, vulvar cancer, vaginal cancer and penile cancer.
Taizhou Yiteng Jingang Pharmaceutical overview
Taizhou Yiteng Jingang Pharmaceutical, is a pharmaceutical manufacturer engaged in the research and development of biological products and chemical drugs. The company is headquartered in China.
For a complete picture of Entinostat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
